| Literature DB >> 34276384 |
Qian Zhuang1, Xin Ye1, Shuang Shen1, Jinnian Cheng1, Yan Shi1, Shan Wu1, Jie Xia1, Min Ning1, Zhixia Dong1, Xinjian Wan1.
Abstract
Cholesterol gallstone (CG) disease has relationships with several metabolic abnormalities. Astragalus polysaccharides (APS) have been shown to have multiple benefits against metabolic disorders. We attempted to uncover the effect and mechanism of action of APS on diet-induced CG formation in mice. Animals were fed a chow diet or lithogenic diet (LD) with or without APS supplementation. The effect of APS on CG formation was evaluated. The level of individual bile acids (BAs) in gallbladder bile and ileum were measured by liquid chromatography-tandem mass spectrometry. Real-time reverse transcription-quantitative polymerase chain reaction and western blotting were used to assess expression of the genes involved in BA metabolism and the enterohepatic circulation. Cecal contents were collected to characterize microbiota profiles. APS ameliorated LD-induced CG formation in mice. APS reduced the level of total cholesterol, bile acid hydrophobicity index and cholesterol saturation index in gallbladder bile. The protective effect of APS might result from reduced absorption of cholic acid in the intestine and increased hepatic BA synthesis. APS relieved the LD-induced activation of the intestinal farnesoid X receptor and decreased ileal expression of fibroblast growth factor 15. In the liver, expression of cytochrome P450 (Cyp) enzyme Cyp7a1 and Cyp7b1 was increased, whereas expression of adenosine triphosphate-binding cassette (Abc) transporters Abcg5 and Abcg8 was decreased by APS. APS improved the diversity of the gut microbiota and increased the relative abundance of the Bacteroidetes phylum. APS had demonstratable benefits against CG disease, which might be associated with enhanced BA synthesis and improved gut microbiota. Our results suggest that APS may be a potential strategy for the prevention of CG disease.Entities:
Keywords: astragalus polysaccharides; bile acids; cholesterol; enterohepatic circulation; gallstones; gut microbiota
Year: 2021 PMID: 34276384 PMCID: PMC8281024 DOI: 10.3389/fphar.2021.701003
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Primer sequences for quantitative real-time PCR analysis.
| Gene | Forward primer | Reverse primer |
|---|---|---|
|
| GGAGCCACGACCCTAGATG | TGCCAAGATAAGGAAGCCAAC |
|
| AGCAGCCTCTGAAGAAGTGAATGG | AGAGCCGCAGAGCCTCCTTG |
|
| ACACCAAGGACAAGCAGCAAGAC | TGGCTCACTTCCACCCACTCC |
|
| ACACGGATGCCTTAAACGAGG | GCAGCCAATCCTTTTCTCAAAC |
|
| TGTTCTGCTGCGAGCTGTTAC | CCGGACTCACGTACTGTTTTT |
|
| GTGTGGATTCCCTTGGGCTTT | CACAACGAACACCTGCTTGG |
|
| CTGGGTCCCCTGCATCTAC | GCCGTCTTGAGCCTGGATAAC |
|
| GGCACTCCGGTTAAGTAACTC | TGTCACTTGGTCGAATTTGTTCA |
|
| GTGCATACCTAGCCAAATCACT | CCAGGCCCATAACCACACATC |
|
| GCTTTTCCAAGATCAAGGCATTT | CGTGGGGATACCGAATTGTCT |
|
| AGATCAGAGAAGACAAGGCACT | CTTTGGTCGGTGTAGCTTGG |
|
| TCTGACTCAGTGATTCTTCGCA | CCCATAAACATCAGCCAGTTGT |
|
| GTCTGTCCCCCAAATGCAACT | CACCCCATAGAAAACATCACCA |
|
| CAAACCTCAGAAGGACCAAACA | GTAGGAGGATTATTCCCGTTGTG |
|
| AGGCAGGACTCATATCAAACTTG | TGAGGGCTATGTCCACTGGG |
|
| AGATGCGGCTCCTTGGAATTA | TGGCTGCTTCTTTCGATTTCTG |
|
| ATGGCGAGAAAGTGGAACGG | CTGACACAGACTGGGATTGCT |
|
| GCTCGGAGGTAGAGGTCTTGT | CCACGCTGACTGGTAGGAA |
|
| CAGCGAGAAACGGAACAGCA | TCAGAGTATCGGAACAGTGTCA |
|
| GCTTGATGTGCTACAAAAGCTG | CGTGGTGATGGTTGAATGTCC |
|
| TGGGTCCCAAGGAGTATGC | GCTCCAAGACTTCACACAGTG |
|
| AGGGCCTCACATCAACAGAG | GCTGACGCTGTAGGACACAT |
|
| CTGTGGAATGGGACTGTACTTC | GTTGGACTGACCACTGTAGGT |
|
| AGGTCGGTGTGAACGGATTTG | TGTAGACCATGTAGTTGAGGTCA |
Cyp7b1, cytochrome P450 7b1; Cyp7a1,cytochrome P450 7a1; Cyp8b1, cytochrome P450 8b1; Cyp27a1, cytochrome P450 27a1; β-klotho, beta-klotho; Mrp2, multidrug resistance protein 2; Mrp3, multidrug resistance protein 3; Mrp4, multidrug resistance protein 4; Oatp1a1, organic anion-transporting polypeptide 1a1; Oatp1a4, organic anion-transporting polypeptide 1a4; Oatp1b2, organic anion-transporting polypeptide 1b2; Bsep, bile acid export pump; Asbt, apical sodium dependent bile acid transporter; Ntcp, Na/taurocholate cotransporting polypeptide; Ostα, organic solute transporter alpha; Ostβ, organic solute transporter beta; Fgf15, fibroblast growth factor 15; Fgfr4, fibroblast growth factor receptor 4; Abcb4, ATP-binding cassette; subfamily B; member 4; Fxr, bile acid receptor; Shp, nuclear receptor subfamily 0 group B member 2; Abcg5, ATP-binding cassette subfamily G member 5; Abcg8, ATP-binding cassette subfamily G member 8; Gapdh, glyceraldehyde-3-phosphate dehydrogenase.
FIGURE 1Bodyweight, and liver weight, and cholesterol gallstone (CG) prevalence. (A) Representative gallbladders per group. (B) CGs from the LD group. (C) CG prevalence. (D) Grades of CG formation. (E) Bodyweight gain. (F) Ratio of liver weight-to-bodyweight. Data are the mean ± SD (n = 10). *p < 0.05, **p < 0.01. Chow, chow diet; LD, lithogenic diet; AL, low-dose APS; AH, high-dose APS.
FIGURE 2Biliary Cholesterol Saturation Index (CSI) and Hydrophobicity Index (HI) of bile acids (BAs) in gallbladder bile. (A) Total cholesterol (TC), BAs and phospholipids (PL) (n = 8–10). (B) CSI (n = 8–10). (C) Analysis of BA species (n = 6). Top-13 most abundant BA species are shown. (D) HI of BAs (n = 6). (E) Total conjugated BAs and unconjugated BAs (n = 6). Data are the mean ± SD, *p < 0.05, **p < 0.01. Chow, chow diet; LD, lithogenic diet; AL, low-dose APS; AH, high-dose APS.
FIGURE 3APS attenuated LD-induced metabolic disorders. (A) Representative images of H&E and Oil Red O staining per group (scale bar: 50 μm). (B) Percentage of Oil Red O positive area. (C) Serum levels of total cholesterol (TC) and triglycerides (TG). (D) Hepatic level of TC. (E) Hepatic level of TG. Data are the mean ± SD (n = 10). *p < 0.05, **p < 0.01. Chow, chow diet; LD, lithogenic diet; AL, low-dose APS; AH, high-dose APS.
FIGURE 4Bile acid (BA) species in the ileum and Fxr–Fgf15 axis. (A) Analyses of BA species (n = 10). Top-13 most abundant BA species are shown. (B) Total conjugated BAs and unconjugated BAs (n = 10). (C) Ileal mRNA expression of Fxr, Shp, and Fgf15 (n = 8). (D) Ileal expression (left panel) and quantification (right panel) of Fgf15 protein (n = 6). Data are the mean ± SD. *p < 0.05, **p < 0.01. Chow, chow diet; LD, lithogenic diet; AH, high-dose APS.
FIGURE 5Expression of the genes involved in cholesterol transport and bile-acid synthesis in the liver. (A) mRNA expression of Cyp7a1, Cyp8b1, Cyp7b1, and Cyp27a1 (n = 8). (B) Protein expression (left panel) and quantification (middle and right panel) of Cyp7a1 and Cyp7b1 (n = 6). (C) mRNA expression of Fgfr4 and β-klotho (n = 8). (D) mRNA expression of Abcg5 and Abcg8 (n = 8). (E) Protein expression (left panel) and quantification (middle and right panel) of Abcg5 and Abcg8 (n = 6). Data are the mean ± SD. *p < 0.05, **p < 0.01. Chow, chow diet; LD, lithogenic diet; AH, high-dose APS.
FIGURE 6APS changed the composition of the gut microbiota. (A) Shannon Index and Simpson Index. (B) Weighted Unifrac principal coordinate analysis (PCoA). (C, D) Multigroup difference analysis of the top-9 most abundant phyla. Data are the mean ± SD (n = 10). *p < 0.05, **p < 0.01. Chow, chow diet; LD, lithogenic diet; AH, high-dose APS.